Page 3 - நொதி News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from நொதி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In நொதி Today - Breaking & Trending Today
Previously approved drugs starting points for COVID-19 therapeutics Researchers in the United States have identified several clinically approved compounds that could be repurposed for the treatment and prevention of coronavirus disease 2019 (COVID-19). By screening a commercial library of drugs that have already been approved by international regulatory agencies, the team identified more than 50 compounds that demonstrated some efficacy in blocking the initial stage of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative agent of COVID-19. The compounds were able to disrupt the binding of a surface viral protein called Spike to its host cell receptor angiotensin-converting enzyme 2 (ACE2). ....
Small molecule inhibitors of SARS-CoV-2 identified by screening Even as the vaccine rollout continues against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), seeking to bring an end to the coronavirus disease 2019 (COVID-19) pandemic, new variants emerge that show immune escape capabilities. Effective and safe drugs thus remain essential to treat severe infections with this virus. A new preprint, released on the bioRxiv server, describes the identification of small molecule inhibitors that block the catalytic activity of the crucial viral non-structural protein 5 (nsp5), using a large-scale screening method. The importance of nsp5 At least nine enzymes of the virus are important for viral proliferation and are thus ideal for the development of antiviral drugs. These enzymes have the same sequence between different coronaviruses, unlike the spike, nucleocapsid and other structural proteins that are less conserved. This makes vaccines based on ....
Researchers provide ultrastructural details of SARS-CoV-2-infected respiratory epithelial cells A team of scientists from the United Kingdom recently investigated the ultrastructural details of the attachment, entry, and budding processes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the human airway epithelium. They have used a highly differentiated air-liquid interface cultures of airway epithelium to thoroughly investigate the viral infection cycle. The study is currently available on the Background SARS-CoV-2, the causative pathogen of coronavirus disease 2019 (COVID-19), is an enveloped RNA virus belonging to the Coronaviridae family. The virus primarily attacks human airway epithelial cells to initiate infection. Mechanistically, the receptor-binding domain (RBD) of the S1 subunit of the viral spike glycoprotein binds to angiotensin-converting enzyme 2 (ACE2), which is ubiquitously expressed at the apical surface of host airway epithelial ce ....
CAL20.C SARS-CoV-2 variant skyrocketing in California evades host immune response The effect of different neutralizing antibodies, both vaccine-elicited and from convalescent sera, suggests new variants are emerging that can evade the human immune response. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to host cells via its spike protein, which has two parts, the S1 and S2 subunits. The S1 subunit has the receptor-binding domain (RBD) and the N-terminal domain (NTD). The RBD binds to the host angiotensin-converting enzyme 2 (ACE2) to infect host cells. Neutralizing antibodies are produced against both the RBD and NTD by infected and vaccinated individuals. Some RBD-specific monoclonal antibodies are currently under clinical trials or approved for use to treat COVID-19 patients. ....
The use of mammalian cell surface display for rapid characterization of SARS-CoV-2 variants A research group from the U.S. demonstrated the practicality of a spike display system in order to accelerate vaccine design, but also to swiftly appraise the effects of mutations in emerging strains of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Their results are currently available on the bioRxiv preprint server. SARS-CoV-2, the causative agent of the ongoing coronavirus disease (COVID-19), uses its spike glycoprotein to interact with angiotensin-converting enzyme 2 (ACE2) in order to fuse cell membrane and viral envelope. The key determinant of host tropism is the S1 subunit of the spike glycoprotein, composed of the receptor-binding domain (RBD) and N-terminal domain (NTD). ....